Circular RNA hsa_circ_0000117 accelerates the proliferation and invasion of gastric cancer cells by regulating the microRNA-337-3p/signal transducer and activator of transcription 3 axis

ABSTRACT

Circular RNA hsa_circ_0000117 is reportedly increased in Gastric cancer (GC), however, its role is unexplored. Hsa_circ_0000117 expression and function in GC was investigated using standard cell phenotypic and expression assays. Pull-down and luciferase reporter assays also elucidated hsa_circ_0000117 mechanisms. In the present study, we observed increased hsa_circ_0000117 and signal transducer and activator of transcription 3 (STAT3) expression, while microRNA-337-3p (miR-337-3p) was decreased in GC cells. Depleted hsa_circ_0000117 decreased GC proliferation and invasion. Hsa_circ_0000117 was also identified as a miR-337-3p sponge. Also, STAT3 was identified as a miR-337-3p target. Similarly, rescue assays indicated STAT3 overexpression (or miR-337-3p inhibition) reversed hsa_circ_0000117 effects in GC progression. Thus, our data suggested hsa_circ_0000117 exhibited oncogene properties in combination with the hsa_circ_0000117/miR-337-3p/STAT3 axis in GC, potentially providing a new therapeutic target for GC.

Abbreviations GC: gastric cancer; STAT3: Signal transducer and activator of transcription 3; circRNA: Circular RNA; miRNA: microRNA; DMEM: Dulbecco’s modified Eagle’s medium; FBS: fetal bovine serum; PVDF: polyvinylidene fluoride; CCK-8: Cell counting kit-8; qRT-PCR: Quantitative real-time PCR; SDS-PAGE: sodium dodecyl sulfate polyacrylamide gel electrophoresis; TNM: TNM Classification of Malignant Tumors; mTOR: mechanistic target of rapamycin; ANOVA: one-way analysis of variance

KEYWORDS:

• Gastric cancer
• hsa_circ_0000117
• miR-337-3p
• STAT3

Highlight

• hsa_circ_0000117 is upregulated in GC tissues and cell line.

• hsa_circ_0000117 promotes the proliferation and invasion of GC cells.

• hsa_circ_0000117/miR-337-3p/STAT3 axis promotes GC progression.

Disclosure statement

The authors declare that they have no financial conflicts of interest.

Additional information

Funding

No funding was received.